Bates A - Search Results

1

Monitoring disease activity using GH and IGF-I in the follow-up of 501 patients with acromegaly.

Sherlock M, Aragon Alonso A, Reulen RC, Ayuk J, Clayton RN, Holder G, Sheppard MC, Bates A, Stewart PM. Sherlock M, et al. Among authors: bates a. Clin Endocrinol (Oxf). 2009 Jul;71(1):74-81. doi: 10.1111/j.1365-2265.2008.03461.x. Epub 2008 Oct 26. Clin Endocrinol (Oxf). 2009. PMID: 19178529

2

Medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues.

Sherlock M, Fernandez-Rodriguez E, Alonso AA, Reulen RC, Ayuk J, Clayton RN, Holder G, Sheppard MC, Bates A, Stewart PM. Sherlock M, et al. Among authors: bates a. J Clin Endocrinol Metab. 2009 Apr;94(4):1255-63. doi: 10.1210/jc.2008-1420. Epub 2009 Jan 21. J Clin Endocrinol Metab. 2009. PMID: 19158203

3

Letter re: Monitoring the response to treatment in acromegaly.

Ayuk J, Sheppard MC, Bates AS, Stewart PM. Ayuk J, et al. J Clin Endocrinol Metab. 2005 Aug;90(8):4980. doi: 10.1210/jc.2005-0187. J Clin Endocrinol Metab. 2005. PMID: 16087964 No abstract available.

4

Mortality in patients with pituitary disease.

Sherlock M, Ayuk J, Tomlinson JW, Toogood AA, Aragon-Alonso A, Sheppard MC, Bates AS, Stewart PM. Sherlock M, et al. Among authors: bates as. Endocr Rev. 2010 Jun;31(3):301-42. doi: 10.1210/er.2009-0033. Epub 2010 Jan 19. Endocr Rev. 2010. PMID: 20086217 Review.

5

A paradigm shift in the monitoring of patients with acromegaly: last available growth hormone may overestimate risk.

Sherlock M, Reulen RC, Aragon-Alonso A, Ayuk J, Clayton RN, Sheppard MC, Hawkins MM, Bates AS, Stewart PM. Sherlock M, et al. Among authors: bates as. J Clin Endocrinol Metab. 2014 Feb;99(2):478-85. doi: 10.1210/jc.2013-2450. Epub 2013 Nov 15. J Clin Endocrinol Metab. 2014. PMID: 24243636

6

Assessment of GH status in acromegaly using serum growth hormone, serum insulin-like growth factor-1 and urinary growth hormone excretion.

Bates AS, Evans AJ, Jones P, Clayton RN. Bates AS, et al. Clin Endocrinol (Oxf). 1995 Apr;42(4):417-23. doi: 10.1111/j.1365-2265.1995.tb02651.x. Clin Endocrinol (Oxf). 1995. PMID: 7750196

7

Assessment of GH status in adults with GH deficiency using serum growth hormone, serum insulin-like growth factor-I and urinary growth hormone excretion.

Bates AS, Evans AJ, Jones P, Clayton RN. Bates AS, et al. Clin Endocrinol (Oxf). 1995 Apr;42(4):425-30. doi: 10.1111/j.1365-2265.1995.tb02652.x. Clin Endocrinol (Oxf). 1995. PMID: 7750197

8

Life expectancy following surgery for pituitary tumours.

Bates AS, Bullivant B, Sheppard MC, Stewart PM. Bates AS, et al. Clin Endocrinol (Oxf). 1999 Mar;50(3):315-9. doi: 10.1046/j.1365-2265.1999.00650.x. Clin Endocrinol (Oxf). 1999. PMID: 10435056

9

Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly.

Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS. Ayuk J, et al. Among authors: bates as. J Clin Endocrinol Metab. 2004 Apr;89(4):1613-7. doi: 10.1210/jc.2003-031584. J Clin Endocrinol Metab. 2004. PMID: 15070920

10

Evidence for the use of igf-I as a predictor of mortality in acromegaly is lacking.

Ayuk J, Sheppard MC, Clayton RN, Bates AS, Stewart PM. Ayuk J, et al. Among authors: bates as. J Clin Endocrinol Metab. 2004 Nov;89(11):5867-8; author reply 5868. doi: 10.1210/jc.2004-1475. J Clin Endocrinol Metab. 2004. PMID: 15531556 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

841 results

Search Page

Filters